The right compound in the right assay at the right time: an integrated discovery DMPK strategy

被引:35
作者
Ballard, Peter [1 ]
Brassil, Patrick [2 ]
Bui, Khanh H. [3 ]
Dolgos, Hugues [4 ]
Petersson, Carl [5 ]
Tunek, Anders [4 ]
Webborn, Peter J. H.
机构
[1] AstraZeneca, Mereside, Alderley Pk SK10 4TG, Cheshire, England
[2] AstraZeneca, Gatehouse Pk, MA USA
[3] AstraZeneca, Wilmington, PA USA
[4] AstraZeneca, Molndal, Sweden
[5] AstraZeneca, Sodertalje, Sweden
关键词
Compound optimization; design-make-test-analyze cycles; human pharmacokinetic and dose predictions; CNS distribution; drug-drug interactions; clearance; absorption; metabolites; transporters; DRUG-DRUG INTERACTIONS; CENTRAL-NERVOUS-SYSTEM; IN-SILICO PREDICTION; BLOOD-BRAIN-BARRIER; INTESTINAL 1ST-PASS METABOLISM; HUMAN CYTOCHROME-P450 2D6; INTRINSIC CLEARANCE DATA; PLASMA-PROTEIN BINDING; HUMAN RENAL CLEARANCE; MARKETED ORAL-DRUGS;
D O I
10.3109/03602532.2012.691099
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The high rate of attrition during drug development and its associated high research and development (R&D) cost have put pressure on pharmaceutical companies to ensure that candidate drugs going to clinical testing have the appropriate quality such that the biological hypothesis could be evaluated. To help achieve this ambition, drug metabolism and pharmacokinetic (DMPK) science and increasing investment have been deployed earlier in the R&D process. To gain maximum return on investment, it is essential that DMPK concepts are both appropriately integrated into the compound design process and that compound selection is focused on accurate prediction of likely outcomes in patients. This article describes key principles that underpin the contribution of DMPK science for small-molecule research based on 15 years of discovery support in a major pharmaceutical company. It does not aim to describe the breadth and depth of DMPK science, but more the practical application for decision making in real-world situations.
引用
收藏
页码:224 / 252
页数:29
相关论文
共 149 条
[51]   Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations [J].
Gabrielsson, Johan ;
Dolgos, Hugues ;
Gillberg, Per-Goran ;
Bredberg, Ulf ;
Benthem, Bert ;
Duker, Goran .
DRUG DISCOVERY TODAY, 2009, 14 (7-8) :358-372
[52]  
Galetin A, 2008, EXPERT OPIN DRUG MET, V4, P909, DOI [10.1517/17425255.4.7.909, 10.1517/17425255.4.7.909 ]
[53]  
García MJ, 2003, METHOD FIND EXP CLIN, V25, P457
[54]   Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data [J].
Gertz, Michael ;
Harrison, Anthony ;
Houston, J. Brian ;
Galetin, Aleksandra .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (07) :1147-1158
[55]   In vitro-in vivo correlation of hepatobiliary drug clearance in humans [J].
Ghibellini, G. ;
Vasist, L. S. ;
Leslie, E. M. ;
Heizer, W. D. ;
Kowalsky, R. J. ;
Calvo, B. F. ;
Brouwer, K. L. R. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) :406-413
[56]   Membrane transporters in drug development [J].
Giacomini, Kathleen M. ;
Huang, Shiew-Mei ;
Tweedie, Donald J. ;
Benet, Leslie Z. ;
Brouwer, Kim L. R. ;
Chu, Xiaoyan ;
Dahlin, Amber ;
Evers, Raymond ;
Fischer, Volker ;
Hillgren, Kathleen M. ;
Hoffmaster, Keith A. ;
Ishikawa, Toshihisa ;
Keppler, Dietrich ;
Kim, Richard B. ;
Lee, Caroline A. ;
Niemi, Mikko ;
Polli, Joseph W. ;
Sugiyama, Yuicchi ;
Swaan, Peter W. ;
Ware, Joseph A. ;
Wright, Stephen H. ;
Yee, Sook Wah ;
Zamek-Gliszczynski, Maciej J. ;
Zhang, Lei .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) :215-236
[57]   Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models [J].
Gleeson, M. Paul ;
Davis, Andrew M. ;
Chohan, Kamaldeep K. ;
Paine, Stuart W. ;
Boyer, Scott ;
Gavaghan, Claire L. ;
Arnby, Catrin Hasselgren ;
Kankkonen, Cecilia ;
Albertson, Nan .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2007, 21 (10-11) :559-573
[58]   Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of HIV Protease Inhibitors [J].
Griffin, Latoya ;
Annaert, Pieter ;
Brouwer, Kim L. R. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (09) :3636-3654
[59]   Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods [J].
Grime, Kenneth H. ;
Bird, James ;
Ferguson, Douglas ;
Riley, Robert J. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 36 (2-3) :175-191
[60]   Regulation of hepatic ABCC transporters by xenobiotics and in disease states [J].
Gu, Xinsheng ;
Manautou, Jose E. .
DRUG METABOLISM REVIEWS, 2010, 42 (03) :482-538